GlassScriptPhysician profile
Michael V Susano
NPI 1063440105
$2,748.58
in general payments reported to CMS, 2019-2025
15 companies · $844 in 2025
The $844 reported for 2025 was more than what 79% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $268 · 2020: $115 · 2021: $51.82 · 2022: $250 · 2023: $604 · 2024: $615 · 2025: $844.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,003 · Education: $60.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,002.56 |
| Education | $60.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $669.97 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Neurocrine Biosciences, INC. | $481.97 | 2019-2025 | Ingrezza |
| Abbvie INC. | $416.73 | 2023-2025 | Vraylar |
| E.R. Squibb & Sons, L.L.C. | $204.85 | 2024-2025 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $198.41 | 2019-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $148.76 | 2021-2024 | Invega Sustenna, Invega Trinza |
| Teva Pharmaceuticals USA, INC. | $136.83 | 2022-2025 | Austedo Xr, Austedo, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $116.19 | 2024-2025 | Caplyta |
| Axsome Therapeutics, INC. | $111.42 | 2023-2024 | Auvelity |
| Sunovion Pharmaceuticals INC. | $73.76 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $66.06 | 2023-2025 | Fanapt, Hetlioz |
| Lundbeck LLC | $52.03 | 2022-2024 | Rexulti |
| Braeburn INC. | $28.88 | 2023 | Brixadi |
| Allergan, INC. | $28.48 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Susano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.